Table 3: The impact of anticoagulant and antiplatelet treatment on QoL assessed by the SF-36 questionnaire in patients with NVAF and VAF (mean scores and 95% CIs).

DomainsAnticoagulantsAntiplatelet AgentsNo antithrombotic therapyp-Value

Patients with NVAF
 Physical functioning57.29 (53.45, 61.13)54.72 (50.94, 58.50)53.71 (49.57, 57.85)0.005
 Physical role functioning34.87 (27.48, 42.25)32.03 (24.76, 39.30)33.29 (25.33, 41.26)0.2601
 Bodily pain72.55 (68.92, 76.18)71.84 (68.27, 75.41)73.60 (69.69, 77.51)0.271
 General health41.76 (38.34, 45.18)42.18 (38.82, 45.54)38.40 (34.72, 42.09)0.002
 Vitality61.54 (58.44, 64.64)60.97 (57.93, 64.02)59.13 (55.79, 62.47)0.070
 Social role functioning59.57 (55.77, 63.38)59.69 (55.94, 63.43)58.67 (54.57, 62.78)0.693
 Emotional role functioning59.35 (51.72, 66.98)54.74 (47.23, 62.24)54.41 (46.19, 62.63)0.026
 Mental health67.92 (65.19, 70.65)66.21 (63.53, 68.89)66.11 (63.11, 69.12)0.040
Patients with VAF
 Physical functioning43.70 (35.79, 51.61)37.96 (29.58, 46.34)34.69 (25.09, 44.29)0.004
 Physical role functioning28.86 (10.57, 47.15)20.99 (2.00, 39.98)19.02 (−1.04, 39.08)0.055
 Bodily pain59.92 (53.44, 66.40)58.86 (51.91, 65.81)54.46 (46.11, 62.80)0.231
 General health36.27 (27.50, 45.04)34.71 (25.60, 43.82)31.96 (22.34, 41.59)0.252
 Vitality46.61 (40.32, 52.90)45.29 (38.62, 51.96)40.54 (32.90, 48.18)0.074
 Social role functioning49.44 (41.63, 57.25)45.06 (36.78, 53.33)42.46 (32.98, 51.94)0.036
 Emotional role functioning44.51 (31.73, 57.30)27.60 (13.90, 41.29)35.68 (19.22, 52.14)0.001
 Mental health53.25 (47.11, 59.39)52.88 (46.38, 59.39)49.02 (41.60, 56.44)0.276

NVAF: non-valvular atrial fibrillation; QoL: quality of life; SF-36: Medical Outcomes Study Short-Form 36 Health Survey; VAF: valvular atrial fibrillation.
means p-values referring to differences among the 3 groups.
“a” indicates significant difference versus patients receiving antiplatelet drugs, and “b” indicates significant difference versus patients not on antithrombotic therapy.